Dapagliflozin Improves Glucose Outcomes in Type 1 Diabetes
FRIDAY, April 26, 2019 -- In patients with type 1 diabetes, treatment with dapagliflozin for 24 weeks improves time in range, mean glucose, and glycemic variability, according to a study published online April 9 in Diabetes Care.
Chantal Mathieu,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Dapagliflozin | Diabetes | Diabetes Type 1 | Endocrinology | Forxiga | Pharmaceuticals | Study